Forbes January 6, 2026
The launch this week of an oral pill version of Wegovy (semaglutide) for weight loss offers convenience and a lower price, which could lead to some patients staying on their medications longer.
The first oral glucagon-like peptide-1 for obesity is now available in the United States following its approval by the Food and Drug Administration in December. GLP-1s help the body regulate appetite, insulin and weight. The FDA label states that these medications are to be used with a reduced-calorie diet along with increased physical activity.
The oral version of Wegovy demonstrated approximately similar effectiveness and side effects in clinical trials as the injectable. Clinical trials show that patients who take the Wegovy pill lose an average of 13.6% of...
Today's Sponsors
Today's Sponsor